Back
Speaker illustration

Professor Marcin Ufnal

AstraZeneca, Warsaw (Poland)

Presentations

AZD3427, a novel relaxin receptor agonist and impact on renal perfusion in patients with heart failure with reduced ejection rraction: the phase 1b Re-Perfuse study design

Event: Heart Failure 2025

Topic: Comorbidities

Session: ePosters in chronic heart failure - comorbidities (1)

Access
Like
Thumbnail

AZD3427, a relaxin mimetic in pulmonary hypertension group 2 associated with left heart disease: design and rationale of the phase 2b Re-PHIRE Study

Event: Heart Failure 2024

Topic: Pharmacotherapy

Session: ePosters in chronic heart failure - treatment 5

Access
Like
Thumbnail

Safety, pharmacokinetics, and pharmacodynamics of AZD3427, a functionally selective long acting relaxin mimetic agonist of the RXFP1 receptor

Event: Heart Failure 2023

Topic: Pharmacotherapy

Session: Chronic heart failure - pharmacotherapy 6

Access
Like
Thumbnail

ESC 365 is supported by

logo Bristol Myers Squibb Explore sponsored resources
logo Novartis Explore sponsored resources
logo Novo Nordisk Explore sponsored resources